Comments
Loading...
Kronos Bio Analyst Ratings and Price Targets | NASDAQ:KRON | Benzinga
Kronos Bio Inc has a consensus price target of $7.31 based on the ratings of 5 analysts. The high is $14 issued by Goldman Sachs on November 10, 2022. The low is $1 issued by Piper Sandler on November 14, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Piper Sandler, and HC Wainwright & Co. on November 14, 2024, October 8, 2024, and August 19, 2024, respectively. With an average price target of $3.08 between Piper Sandler, Piper Sandler, and HC Wainwright & Co., there's an implied 262.75% upside for Kronos Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Goldman Sachs
Berenberg
1calculated from analyst ratings
Analyst Ratings for Kronos Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/14/2024 | Buy Now | 17.65% | Piper Sandler | Edward Tenthoff50% | $6 → $1 | Downgrade | Overweight → Neutral | Get Alert |
| 11/14/2024 | Buy Now | — | TD Cowen | Floris Van Dijkum57% | — | Downgrade | Buy → Hold | Get Alert |
| 10/08/2024 | Buy Now | 605.88% | Piper Sandler | Edward Tenthoff50% | $6 → $6 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 164.71% | HC Wainwright & Co. | Robert Burns40% | $2.25 → $2.25 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | 164.71% | HC Wainwright & Co. | Robert Burns40% | $2.25 → $2.25 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 164.71% | HC Wainwright & Co. | Robert Burns40% | $2.5 → $2.25 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | 605.88% | Piper Sandler | Edward Tenthoff50% | $7 → $6 | Maintains | Overweight | Get Alert |
| 12/19/2023 | Buy Now | 194.12% | HC Wainwright & Co. | Robert Burns40% | $9 → $2.5 | Maintains | Buy | Get Alert |
| 11/27/2023 | Buy Now | 958.82% | HC Wainwright & Co. | Robert Burns40% | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | 958.82% | HC Wainwright & Co. | Robert Burns40% | $10 → $9 | Maintains | Buy | Get Alert |
| 04/17/2023 | Buy Now | 1076.47% | HC Wainwright & Co. | Robert Burns40% | → $10 | Reiterates | → Buy | Get Alert |
| 11/18/2022 | Buy Now | 1076.47% | HC Wainwright & Co. | Robert Burns40% | $36 → $10 | Maintains | Buy | Get Alert |
| 11/10/2022 | Buy Now | 1547.06% | Goldman Sachs | Salveen Richter52% | $25 → $14 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 723.53% | Piper Sandler | Edward Tenthoff50% | $13 → $7 | Maintains | Overweight | Get Alert |
| 09/14/2022 | Buy Now | 1311.76% | Berenberg | Zhiqiang Shu22% | → $12 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 2605.88% | Goldman Sachs | Salveen Richter52% | $35 → $23 | Maintains | Buy | Get Alert |
| 05/23/2022 | Buy Now | 1429.41% | Piper Sandler | Edward Tenthoff50% | $30 → $13 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Kronos Bio (KRON) stock?
The latest price target for Kronos Bio (NASDAQ:KRON) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $1.00 expecting KRON to rise to within 12 months (a possible 17.65% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kronos Bio (KRON)?
The latest analyst rating for Kronos Bio (NASDAQ:KRON) was provided by Piper Sandler, and Kronos Bio downgraded their neutral rating.
When was the last upgrade for Kronos Bio (KRON)?
There is no last upgrade for Kronos Bio
When was the last downgrade for Kronos Bio (KRON)?
The last downgrade for Kronos Bio Inc happened on November 14, 2024 when Piper Sandler changed their price target from $6 to $1 for Kronos Bio Inc.
When is the next analyst rating going to be posted or updated for Kronos Bio (KRON)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kronos Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kronos Bio was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.
Is the Analyst Rating Kronos Bio (KRON) correct?
While ratings are subjective and will change, the latest Kronos Bio (KRON) rating was a downgraded with a price target of $6.00 to $1.00. The current price Kronos Bio (KRON) is trading at is $0.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.